Current Research in Translational Medicine最新文献

{"title":"CAR-T cells targeting IL-1RAP produced in a closed semiautomatic system are ready for the first phase I clinical investigation in humans","authors":"Clémentine Nicod ,&nbsp;Mathieu Neto da Rocha ,&nbsp;Walid Warda ,&nbsp;Xavier Roussel ,&nbsp;Rafik Haderbache ,&nbsp;Evan Seffar ,&nbsp;Rim Trad ,&nbsp;Lucie Bouquet ,&nbsp;Mathieu Goncalves ,&nbsp;Léa Bosdure ,&nbsp;Marie-Charlotte Laude ,&nbsp;Mélanie Guiot ,&nbsp;Christophe Ferrand ,&nbsp;Marina Deschamps","doi":"10.1016/j.retram.2023.103385","DOIUrl":"10.1016/j.retram.2023.103385","url":null,"abstract":"<div><h3>Purpose of the study</h3><p>The use of chimeric antigen receptor (CAR)-T cells has demonstrated excellent results in B-lymphoid malignancies. The Advanced Therapy Medicinal Products (ATMP) status and good manufacturing practice (GMP) of CAR-T cells require particular conditions of production performed in a pharmaceutical establishment. Our team developed a new medical drug candidate for acute myeloid leukemia (AML), a CAR targeting interleukin-1 receptor accessory protein (IL-1RAP) expressed by leukemia stem cells, which will need to be evaluated in a phase I-IIa clinical trial. During the preclinical development phase, we produced IL-1RAP CAR-T cells in a semi-automated closed system (CliniMACSࣨ Prodigy) using research grade lentiviral particles.</p></div><div><h3>Patients and the methods</h3><p>The purpose of this work was to validate our production process and to characterize our preclinical GMP-like medicinal product. IL-1RAP CAR-T cells were produced from healthy donors in 9 days, either in an semi-automated closed system (with GMP-like compliant conditions) or according to another research protocols, which was used as a reference.</p></div><div><h3>Results</h3><p>Based on phenotypic, functional and metabolic analyses, we were able to show that the final product is ready for clinical use. Finally, in a xenograft AML murine model, we demonstrated that the IL-1RAP CAR-T cells generated in a GMP-like environment could eliminate tumor cells and increase overall survival.</p></div><div><h3>Conclusion</h3><p>We demonstrated that our IL-1RAP CAR-T cell preclinical GMP-like production process meets standard regulatory requirements in terms of CAR-T cell number, subpopulation phenotype and cytotoxic functionality. Our CAR-T cell production process was validated and can be used to produce medicinal IL-1RAP CAR-T cells for the first phase I clinical trial.</p></div>","PeriodicalId":54260,"journal":{"name":"Current Research in Translational Medicine","volume":"71 2","pages":"Article 103385"},"PeriodicalIF":4.1,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9647553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Timing of cyclosporine administration for GvHD prophylaxis in haploidentical stem cell transplantation setting: Single center experience","authors":"Jean El Cheikh ,&nbsp;Layal Sharrouf ,&nbsp;Mahdi Hamade ,&nbsp;Khodr Terro ,&nbsp;Ghassan Bidaoui ,&nbsp;Maya Charafeddine ,&nbsp;Fatima Ismail ,&nbsp;Ammar Zahreddine ,&nbsp;Nour Moukalled ,&nbsp;Imane Abou Dalle ,&nbsp;Ali Bazarbachi","doi":"10.1016/j.retram.2023.103387","DOIUrl":"10.1016/j.retram.2023.103387","url":null,"abstract":"","PeriodicalId":54260,"journal":{"name":"Current Research in Translational Medicine","volume":"71 2","pages":"Article 103387"},"PeriodicalIF":4.1,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9651750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"New scenarios in Vacuoles, E1 enzyme, X linked, Autoinflammatory, Somatic (VEXAS) syndrome: Evolution from myelodysplastic syndrome to acute myeloid leukemia","authors":"Giorgia Battipaglia ,&nbsp;Annamaria Vincenzi ,&nbsp;Giulia Falconi ,&nbsp;Alessia Fiore ,&nbsp;Francesco D'Agostino ,&nbsp;Raffaella Iannotta ,&nbsp;Francesco Grimaldi ,&nbsp;Carmelo Gurnari ,&nbsp;Elisa Galossi ,&nbsp;Elena Crisà ,&nbsp;Francesca Bonello ,&nbsp;Giulia Scalia ,&nbsp;Barbara Izzo ,&nbsp;Maria Teresa Voso ,&nbsp;Fabrizio Pane","doi":"10.1016/j.retram.2023.103386","DOIUrl":"10.1016/j.retram.2023.103386","url":null,"abstract":"","PeriodicalId":54260,"journal":{"name":"Current Research in Translational Medicine","volume":"71 2","pages":"Article 103386"},"PeriodicalIF":4.1,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9702324","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Regulatory factors involved in Th17/Treg cell balance of immune thrombocytopenia","authors":"Masoud Kargar ,&nbsp;Mehdi Torabizadeh ,&nbsp;Daryush Purrahman ,&nbsp;Zeinab Deris Zayeri ,&nbsp;Najmaldin Saki","doi":"10.1016/j.retram.2023.103389","DOIUrl":"10.1016/j.retram.2023.103389","url":null,"abstract":"<div><p>Immune thrombocytopenia is a common heterogeneous autoimmune disease that is characterized by decreasing peripheral blood platelet counts and increasing risk of bleeding. Studies have shown that an imbalance between T helper 17 (Th17) and Regulatory T (Treg) cells differentiated from CD4⁺T-cells is a key factor influencing the development and pathogenesis of immune thrombocytopenia. Th17 cells promote the development of chronic inflammatory disorders and induce autoimmune diseases, whereas Treg cells regulate immune homeostasis and prevent autoimmune diseases. Several regulators affecting the production and maintenance of these cells are also essential for proper regulation of Th17/Treg balance; these regulatory factors include cell surface proteins, miRNAs, and cytokine signaling. In this review, we focus on the function and role of balance between Th17 and Treg cells in immune thrombocytopenia, the regulatory factors, and therapeutic goals of this balance in immune thrombocytopenia.</p></div>","PeriodicalId":54260,"journal":{"name":"Current Research in Translational Medicine","volume":"71 2","pages":"Article 103389"},"PeriodicalIF":4.1,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9640751","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Are we there yet? cellular therapies for cutaneous T cell lymphoma","authors":"Pinar Ataca Atilla ,&nbsp;Erden Atilla","doi":"10.1016/j.retram.2023.103390","DOIUrl":"10.1016/j.retram.2023.103390","url":null,"abstract":"<div><p><span><span>Cutaneous T cell<span><span> lymphomas (CTCLs) are a heterogenous group of skin-involved T-cell non-Hodgkin lymphoma which Mycosis Fungoides and </span>Sezary Syndrome<span> are the most common variants. Despite considerable progress in distinguishing the pathophysiology<span>, the treatment options are still limited for advanced-stage disease. Recent approval of novel agents such as </span></span></span></span>vorinostat<span>, brentuximab vedotin<span> and mogamulizumab paved a way. </span></span></span>Allogeneic hematopoietic stem cell transplantation has been shown to be a feasible option in selected advanced-stage CTCL patients. Chimeric antigen receptor (CAR) T cells have been promising for the treatment of B-cell tumors and have been approved for second-line treatment in non-Hodgkin's lymphoma. Although several obstacles still need to be addressed, CAR T cell treatment for CTCLs seems not far off. This review discusses new discoveries in pathophysiology, the state of cellular therapies in current practice, challenges for cellular treatment in advanced CTCL, and how to overcome these challenges.</p></div>","PeriodicalId":54260,"journal":{"name":"Current Research in Translational Medicine","volume":"71 2","pages":"Article 103390"},"PeriodicalIF":4.1,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9647176","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Plasma cell-directed therapy and anti-HLA antibody production: A successful combination?","authors":"Martina Soldarini ,&nbsp;Annamaria Cafro ,&nbsp;Paola Bertazzoni ,&nbsp;Marialuisa Pioltelli ,&nbsp;Giorgia Cornacchini ,&nbsp;Giuliana Lando ,&nbsp;Elisabetta Sommaruga ,&nbsp;Antonio Milano ,&nbsp;Roberto Cairoli ,&nbsp;Silvano Rossini ,&nbsp;Roberto Crocchiolo","doi":"10.1016/j.retram.2023.103391","DOIUrl":"10.1016/j.retram.2023.103391","url":null,"abstract":"","PeriodicalId":54260,"journal":{"name":"Current Research in Translational Medicine","volume":"71 2","pages":"Article 103391"},"PeriodicalIF":4.1,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9647204","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Failure to bispecific-antibody therapy is associated with a short survival in highly pre-treated patients with aggressive B-Cell Lymphomas","authors":"Kohar Kevork,&nbsp;Melanie Gouin,&nbsp;Valentin Letailleur,&nbsp;Patrice Chevallier,&nbsp;Cyrille Touzeau,&nbsp;Thomas Gastinne,&nbsp;Bénédicte Piron,&nbsp;Benoît Tessoulin","doi":"10.1016/j.retram.2023.103388","DOIUrl":"10.1016/j.retram.2023.103388","url":null,"abstract":"","PeriodicalId":54260,"journal":{"name":"Current Research in Translational Medicine","volume":"71 2","pages":"Article 103388"},"PeriodicalIF":4.1,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10005840","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Management of Philadelphia chromosome positive acute lymphoblastic leukemia in the current era","authors":"Talha Badar ,&nbsp;Hassan Alkhateeb ,&nbsp;Mahmoud Aljurf ,&nbsp;Mohamed A. Kharfan-Dabaja","doi":"10.1016/j.retram.2023.103392","DOIUrl":"10.1016/j.retram.2023.103392","url":null,"abstract":"<div><p><span><span>Before the advent of tyrosine kinase inhibitors (TKI) the outcome of </span>Philadelphia chromosome positive (Ph</span>⁺<span>) acute lymphoblastic leukemia (ALL) was dismal. The TKI combination with induction regimens has greatly improved the long-term outcome of Ph</span>⁺<span><span><span><span> ALL, specifically ponatinib a most potent TKI in combination with HyperCVAD (hyperfractionated </span>cyclophosphamide<span>, vincristine, </span></span>doxorubicin, and dexamethasone) chemotherapy has demonstrated 5 years overall survival up to 75%. Historically, </span>allogeneic hematopoietic stem cell transplantation<span><span> (allo-HSCT) used to be the only potential curative option, recent data suggest that patients who achieve complete molecular remission within 3 months of TKI based induction therapies can achieve comparable overall survival with or without allo-HSCT. Intensive </span>cytotoxic chemotherapy may not be the desirable treatment option in elderly Ph</span></span>⁺<span> ALL patients due to anticipated tolerance, recently in a phase II study, “chemotherapy free” combinations such as blinatumomab (bispecific anti-CD3 and anti-CD19 monoclonal antibody) with ponatinib in treatment naïve Ph</span>⁺ ALL patients have shown a complete response rate of 95% and 2 years overall survival of 93%. In this review we have highlighted the evolving treatment landscape of Ph⁺ ALL and what to look for in future.</p></div>","PeriodicalId":54260,"journal":{"name":"Current Research in Translational Medicine","volume":"71 2","pages":"Article 103392"},"PeriodicalIF":4.1,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10005862","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Current research in translational medicine - biostatistical recommendations for authors","authors":"Michal Ordak","doi":"10.1016/j.retram.2023.103381","DOIUrl":"10.1016/j.retram.2023.103381","url":null,"abstract":"","PeriodicalId":54260,"journal":{"name":"Current Research in Translational Medicine","volume":"71 2","pages":"Article 103381"},"PeriodicalIF":4.1,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9666191","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Current status of producing autologous hematopoietic stem cells","authors":"Zhonglin Li,&nbsp;Ling Yang","doi":"10.1016/j.retram.2023.103377","DOIUrl":"10.1016/j.retram.2023.103377","url":null,"abstract":"<div><p><span>Hematopoietic stem cells (HSCs) transplantation is an established therapy for many diseases of the hematopoietic system, for example aplastic anemia, acute myeloid leukemia and acute lymphoblastic leukemia. With the development of the HSCs<span> research, HSCs provide an attractive method for treating hereditary blood disorders and immunotherapy of cancer by introducing gene modification. Compared with allogenic HSCs transplantation, using autologous HSCs or HSCs from induced pluripotent stem cells (iPSCs) would eliminate the probability of alloimmunization and transfusion-transmitted infectious diseases. The methods for obtaining autologous HSCs include amplifying patients’ HSCs or inducing patients’ somatic cells to HSCs (graph abstract). However, the biggest problem is inducing HSCs to proliferate </span></span><em>in vitro</em> and maintaining their stemness at the same time. Although many tests have been made to transform iPSCs to HSCs, the artificially generated HSCs still have substantial disparity compared with physiological HSCs. This review summarized the application status and obstacles to implantation of autologous HSCs and iPSC-derived HSCs. Meanwhile, we summarized the latest research progress in HSCs amplification and iPSCs reprogramming methods, which will help to solve the problems mentioned above.</p></div>","PeriodicalId":54260,"journal":{"name":"Current Research in Translational Medicine","volume":"71 1","pages":"Article 103377"},"PeriodicalIF":4.1,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9537548","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}